Pralsetinib (BLU-667) Pralsetinib (BLU-667, CS 3009, Gavreto) is a highly potent and selective RET (c-RET) inhibitor with an IC50 of 0.4 nM for WT RET. It also demonstrates potent activity (IC50 0.4 nmol/L) against common oncogenic RET alterations, incl In vitro
BLU-667 is at least 100-fold more selective for RET over 96% of kinases tested (a panel of 371 kinases). BLU-667 specifically abrogates RET signaling in RET-altered cancers from diverse lineages. RET pathway inhibition with BLU-667 also more potently inhibits proliferation of RET-altered cell lines relative to multikinase inhibitors.
In vivo
In vivo, BLU-667 potently inhibits growth of NSCLC and thyroid cancer xenografts driven by various RET mutations and fusions without inhibiting VEGFR2. BLU-667 is well tolerated throughout the in vivo studies. Cell Data
cell lines:
Concentrations:0-1 μM
Incubation Time:90 minutes
Powder Purity:≥98%
规格
别名
普拉替尼 (BLU-667)
英文别名
CS 3009, Gavreto
规格或纯度
Moligand™, 10mM in DMSO
英文名称
Pralsetinib (BLU-667)
生化机理
Pralsetinib(BLU-667,CS 3009,Gavreto)是一种高效选择性 RET(c-RET)抑制剂,对 WT RET 的 IC50 为 0.4 nM。它对常见的致癌 RET 改变(包括 RET (M918T))也有很强的活性(IC50 0.4 nmol/L)。